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ABSTRACT – PURPOSE: Circulating microparticles have been highlighted as biomarkers of 
cardiovascular disease state and progression. The aim of this study was to evaluate the effects of curcumin 
on microparticle release from endothelial cells undergoing TNF-induced cell activation and apoptosis. 
METHODS: This study evaluated the effects of curcumin on microparticle release, cytotoxicity, apoptosis, 
cell adhesion molecule expression and monocyte adhesion in EAhy926 human endothelial cells. RESULTS: 
The results showed that the numbers of microparticles were increased by tumour necrosis factor (TNF) or 
the combination of TNF and cycloheximide (CHX). Curcumin attenuated microparticle release caused by 
TNF or TNF plus CHX treatments. The pretreatment by curcumin not only negated the accelerated cell death 
and apoptosis caused by TNF and CHX, but also diminished TNF-induced cell activation, as assessed by 
reduced surface expression of intercellular adhesion molecule 1, and adhesion of monocytes to endothelial 
monolayers. CONCLUSION: Curcumin reduced microparticle release from endothelial cells undergoing 
cell activation and apoptosis, which supports its protective role in TNF-associated endothelial dysfunction, 
and highlights its potential use as a nutraceutical agent for vascular inflammatory diseases. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________________________________ 
 
INTRODUCTION 
 
Turmeric (Curcuma longa Linn.) has been used 
extensively as a spice and herbal medicine for 
thousands of years. Medicine for many years. 
Curcumin (diferuloylmethane) is a yellowish 
polyphenolic component derived from the rhizome 
of turmeric. A large body of evidence has supported 
the anti-inflammatory effects and anti-cancer 
properties of curcumin (1-3). There is also 
accumulating evidence for its beneficial effects in 
cardiovascular diseases (1-4). In particular, it has 
been shown to block the production and effects of 
tumour necrosis factor (TNF) (5). 
TNF (previously known as TNF-α) is a 
pleiotropic pro-inflammatory cytokine implicated 
in cardiovascular disease and endothelial 
dysfunction (6). TNF induces endothelial cell 
activation through the upregulation of cell adhesion 
molecule expression and promoting 
monocyte-endothelium interactions (7). On the 
other hand, TNF can exacerbate apoptosis and 
cytotoxicity in the presence of transcription (e.g. 
actinomycin D) and translation (e.g. cycloheximide 
(CHX)) inhibitors (8,9). Cell activation and 
apoptosis are the two cellular processes that can 
increase the shedding of cell-derived microparticles. 
Several reports have demonstrated that TNF 
strongly enhances microparticle formation (10-13). 
Cell-derived microparticles, also known as “cell 
dust”, are small vesicles shed from the plasma 
membrane of activated or apoptotic cells (14,15). 
Circulating microparticles originate from various 
cell types, including platelets, monocytes, 
endothelial cells, lymphocytes, erythrocytes and 
granulocytes (16,17). Microparticles play an 
important role in cell-to-cell communications by 
transferring biological signals from host cells to the 
neighbouring cells, and thus having a substantial 
role on cellular homeostasis of the targeted cells 
(18). Elevated levels of circulating microparticles 
have been highlighted as independent predictors for  
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cardiovascular disease events (19).  
Although scientific evidence supports the 
cardioprotective effects of curcumin, the effect of 
curcumin on microparticle formation has not yet 
been investigated. Hence, the aim of this study was 
to evaluate the effects of curcumin on microparticle 
release from endothelial cells undergoing 
TNF-induced cell activation and apoptosis.  
 
MATERIALS AND METHODS 
 
Materials  
Human TNF recombinant protein was purchased 
from Cell Signaling Technology (USA). Curcumin 
(> 98% HPLC) was purchased from Chengdu 
Biopurify Phytochemicals Ltd. (China). 
Cycloheximide was purchased from Santa Cruz 
Biotechnology (USA). CellTiter® Glo Luminescent 
Cell Viability Assay Kit was purchased from 
Promega (Australia). JC-1 was purchased from 
Biotium (USA). R-Phycoerythrin (PE)-conjugated 
antibodies (CD54) were purchased from 
e-Bioscience (USA). Fluorescein isothiocyanate 
(FITC) Annexin V apoptosis detection kit was 
purchased from BD Pharmingen (Australia). Cell 
culture reagents were from Life Technology 
(Australia), and other chemicals were from 
Sigma-Aldrich (Australia) unless otherwise stated. 
 
Cell line and culture conditions 
Human cardiovascular endothelial cell line 
(EAhy926) was kindly provided by Dr Shanhong 
Ling (Monash University Central Clinical School, 
Australia). The cell line was cultured in 
DMEM/Ham’s F12 containing 15 mM HEPES and 
L-glutamine, supplemented with 10% foetal bovine 
serum and 100 U/mL of penicillin and streptomycin 
(Gibco BRL, Australia) (20). Human acute 
monocytic leukaemia cells (THP-1) were kindly 
provided by Dr Prasad Kota (University of Sydney, 
Australia) and were cultured in RPMI-1640 
medium containing L-glutamine supplemented with 
10% foetal bovine serum and 100 U/mL of 
penicillin and streptomycin (Gibco BRL, Australia). 
Both cell lines were grown in a 5% CO2 -humidified 
incubator at 37°C. 
 
Cell viability assays 
Cell viability measurement by MTT dye reduction 
assay was performed as previously described (20). 
Briefly, EAhy926 cells were exposed to TNF ± 
cycloheximide (CHX) for 24 hours after 
pretreatment with curcumin (final DMSO 
concentration 0.1%) for one hour. MTT (final 
concentration 0.5 mg/mL) solution was added and 
incubated for 4 hours at 37°C. Dimethyl sulfoxide 
was then added to dissolve the insoluble formazan 
crystal. The absorbance was measured at 550 nm. 
Cell viability was also assessed using the 
CellTiter®-Glo Luminescent Cell Viability Assay 
Kit. Briefly, 100 μL of CellTiter-Glo working 
reagent was added to each well and mixed on a 
microplate shaker for 10 mins. Luminescence was 
monitored using a luminescence microplate reader.  
 
Flow cytometric analysis of cell-derived 
microparticles 
Cell-derived microparticles were assessed by flow 
cytometric analysis (14). Briefly, EAhy926 cells 
were exposed to TNF ± CHX for 24 hours after 
pretreatment with curcumin for one hour. Cell 
culture supernatant was collected and stained with 
Annexin-V-FITC and Annexin-V binding buffer. 
Samples were then mixed with a known 
concentration of 2.5 µm AlignFlowTM flow 
cytometry alignment beads (Invitrogen, Australia) 
as an internal control, and 50,000 events were 
analysed using the FACSCalibur flow cytometer 
(BD Biosciences, Australia) and WEASEL 
Software Version 3.0.2 (Walter and Eliza Hall 
Institute, Australia). Particulates (< 1 µm) were 
gated as a population using the upper limits of 0.8 
µm and lower limits of 1.1 µm using calibrated 
latex beads with particle size of 0.8 and 1.1 µm 
(Sigma-Aldrich, Australia). The number of positive 
Annexin-V-FITC fluorescent events within the 
gated population was considered as microparticles. 
The number of positive events was normalised to 
the internal control beads and was expressed as fold 
change relative to control. 
 
Flow cytometric analyses for cell adhesion 
molecules expressions 
Surface expressions of cell adhesion molecule were 
performed using flow cytometry. Briefly, EAhy926 
cells were exposed to TNF for 4 hours after 
pretreatment with curcumin for one hour. Cells 
were harvested and collected by centrifugation at 
500 x g for 5 mins. The cell pellet was stained with 
CD54-PE in serum containing medium for 30 mins 
on ice. The pellet was then washed three times, and 
the samples were subjected to flow cytometric 
analyses. Ten thousand (10,000) cells were 
analysed using the FACSCalibur flow cytometer. 
The results are presented as mean fluorescence 
intensity and the percentage of cells with positive 
staining. 
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Monocyte-endothelial adhesion assay 
Monocyte-endothelial adhesion assay was 
performed as previously described (21). Briefly, the 
confluent endothelial monolayer was stimulated 
with TNF for 4 hours after pretreatment with 
curcumin for one hour. The cells were then 
co-cultured with THP-1 cells at 37°C for 30 min. 
After the incubation period, the wells were washed 
gently three times with PBS and fixed with 3% 
buffered paraformaldehyde for 20 minutes. The 
cells were then stained with 0.2% crystal violet in 
20% methanol for 5 minutes. The excess crystal 
violet stain was rinsed with distilled water for 4-5 
times and air-dried. Glacial acetic acid (33%) in 
Milli-Q water was added to extract the crystal 
violet stain. The absorbance was then measured at 
595 nm.  
 
Flow cytometric analysis for Annexin V/PI 
staining  
Apoptosis was detected by flow cytometric analysis 
using a commercial FITC Annexin V apoptosis 
detection kit. Briefly, EAhy926 cells were exposed 
to TNF plus CHX for 24 hours after pretreatment 
with curcumin for one hour. Both detached and the 
attached monolayer cells were collected by 
centrifugation at 500 x g for 5 minutes and 
resuspended in Annexin-V binding buffer. The cells 
were then incubated with FITC-Annexin-V and 
propidium iodide (PI) for 15 minutes, and 10,000 
cells were analysed within 1 hour using the 
FACSCalibur flow cytometer. The percentage of 
apoptotic cells were quantified by combining both 
early (FITC-Annexin-V+/PI-) and late 
(FITC-Annexin-V+/PI+) apoptotic cells, while 
negative staining for both FITC-Annexin-V and PI 
were recognised as healthy cells. 
 
Flow cytometric analysis of mitochondrial 
membrane potential 
Mitochondrial membrane potential was assessed by 
flow cytometric analysis (22). Briefly, EAhy926 
cells were exposed to TNF plus CHX for 24 hours 
after pretreatment with curcumin for one hour. Both 
detached and the attached monolayer cells were 
collected by centrifugation at 500 x g for 5 minutes. 
The cell pellet was then incubated in JC-1 solution 
for 15 minutes at 37oC, and 10,000 cells were 
analysed using the FACSCalibur flow cytometer. 
Carbonyl cyanide m-chlorophenyl hydrazone 
(CCCP) (500 μM) was used as a positive control 
for gating. 
 
STATISTICAL ANALYSES 
 
Statistical comparisons were performed using 
GraphPad Version 5.02 (USA). The data was 
analysed by one-way analysis of variance (ANOVA) 
followed by Newman-Keuls post hoc test. Data was 
expressed as mean ± S.E.M. P < 0.05 was 
considered as statistically significant. 
 
RESULTS  
 
TNF enhanced microparticle release 
The activities of TNF can be switched from cell 
activation to cell death in the presence of CHX. To 
examine the effects of TNF, EAhy926 cells were 
treated with TNF ± CHX for 24 hours, and cell 
viability was evaluated using the MTT dye 
reduction assay. Neither TNF (1-10 ng/mL), nor 
CHX (100 ng/mL) showed significant influences on 
cell viability (Fig. 1A). As expected (8), treatment 
with TNF (10 ng/mL) plus CHX (100 ng/mL) 
significantly exacerbated cell death in EAhy926 
cells (P < 0.05). 
Cell-derived microparticles can be released 
following cell activation and apoptosis (14). To 
study the effects of TNF on microparticle release, 
EAhy926 cells were treated with TNF and/or CHX 
for 24 hours, and the microparticle levels in cell 
culture supernatant were evaluated by flow 
cytometry. Microparticles are commonly 
distinguished by Annexin V positive (i.e. 
phosphatidylserine (PS) positive) submicron 
membrane vesicles (<1 μm in diameter) (14). 
Therefore, the microparticles in this study were 
defined as vesicles positive to FITC-Annexin V and 
their sizes were less than 1 μm (Fig. 1B-C). Our 
results showed that TNF (10 ng/mL) increased the 
numbers of microparticles by 2.05 ± 0.37 fold 
compared to the control group (Fig. 1D). The 
combined treatment of TNF (10 ng/mL) and CHX 
(100 ng/mL) significantly elevated the 
microparticle level to 3.12 ± 0.11 fold (Fig. 1E).  
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Figure 1. Effects of TNF and cycloheximide on endothelial cell viability and microparticle release. (A) Cell 
viability, as determined by MTT dye reduction assay, following incubation with TNF, CHX or TNF plus CHX for 24 
hours in EAhy926 cells. Cell viability was expressed as a percentage compared to control. All results were expressed as 
mean ± S.E.M. from three separate experiments. *P < 0.05 compared to control. For the detection of microparticles, (B) 
latex beads of different sizes (0.8 and 1.1 μm) were used to gate particles with diameter less than 1 μm from the 
population, while 2.5 μm beads were used as internal control beads. (C) Gated particles (<1 μm) in the left panel were 
stained with FITC-Annexin V to generate a sub-population that is positively stained with Annexin V as shown in the 
right panel. Using this method, microparticle levels in the cell culture supernatant of EAhy926 endothelial cells treated 
with (D) TNF and (E) TNF plus CHX for 24 hours were analysed by flow cytometric analysis following staining with 
FITC-Annexin V. The number of Annexin V positive microparticles was normalised with the internal control beads and 
was expressed as fold change relative to control. All results were expressed as mean ± S.E.M. from quadruplicate 
samples. * P < 0.05 compared to control. 
 
 
Curcumin reduced TNF-enhanced microparticle 
release 
Curcumin treatment up to 5 μM for 24 hours 
showed >95% cell viability (Fig. 2A). To evaluate 
the effects of curcumin on TNF ± CHX -enhanced 
microparticle release, EAhy926 cells were 
pretreated with curcumin (1 – 5 μM) for one hour 
and then incubated with TNF (10 ng/mL) ± CHX 
(100 ng/mL) for 24 hours. Our results showed that 
curcumin concentration-dependently reduced 
TNF-enhanced microparticle release (Fig. 2B). 
Similar results were also observed in the TNF plus 
CHX treatment group where curcurmin reduced the 
microparticle levels in a concentration-dependent 
manner (Fig. 2C). 
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Figure 2. Effects of curcumin on EAhy926 cell microparticle levels. (A) Cell viability, as determined by MTT dye 
reduction assay, following incubation with curcumin for 24 hours in EAhy926 cells. Cell viability was expressed as a 
percentage compared to control. All results were expressed as mean ± S.E.M. from three separate experiments. To 
determine the effects of curcumin on microparticle levels, EAhy926 endothelial cells were pretreated with curcumin for 
one hour and then exposed to (B) TNF alone and (C) TNF plus CHX for 24 hours. Cell culture supernatant was 
analysed by flow cytometric analysis following staining with FITC-Annexin V. The number of Annexin V positive 
microparticles was normalised with the internal control beads and was expressed as fold change relative to control. All 
results were expressed as mean ± S.E.M. from quadruplicate samples. # P < 0.05 compared to control. * P < 0.05 
compared to TNF alone or TNF plus CHX treated-group. 
 
 
Curcumin attenuated endothelial cell activation 
Endothelial cell activation refers to a change in the 
endothelial cell phenotype in response to cellular 
stress and is denoted by an increase in 
endothelial-leukocyte interactions and the 
up-regulation of cell adhesion molecules (e.g. 
ICAM-1, VCAM-1 and E-selectin) (23). To 
investigate the effects of curcumin on endothelial 
cell activation, ICAM-1 surface expression and 
monocyte adhesion to endothelial monolayer were 
evaluated. EAhy926 cells were pretreated with 
curcumin for 1 hour and then exposed to TNF (10 
ng/mL) for 4 hours. As shown in Fig 3A-B, 
pretreatment with curcumin (2.5 - 5 μM) 
significantly attenuated the surface expression of 
ICAM-1 and reduced the proportion of cells with 
up-regulated ICAM-1 expression. To demonstrate 
the adhesion capacity of TNF-stimulated EAhy926 
cells, THP-1 monocytic cells were co-cultured with 
EAhy926 cells. Our results showed that curcumin 
(2.5 - 5 μM) significantly reduced the adhesion of 
THP-1 monocytic cells onto the TNF-stimulated 
EAhy926 endothelial monolayer (Fig. 3C).  
 
Curcumin attenuated TNF plus CHX-induced cell 
death 
As described, CHX sensitised TNF-induced 
cytotoxicity and exacerbated microparticle release 
from EAhy926 cells, while pretreatment with 
curcumin reduced TNF plus CHX-induced 
microparticle release. To study the effects of 
curcumin on TNF plus CHX-induced endothelial 
cell death, EAhy926 cells were pretreated with 
curcumin for 1 hour and exposed to TNF (10 
ng/mL) plus CHX (100 ng/mL) for 24 hours. As 
revealed by the MTT dye reduction assay, curcumin 
(2.5 - 5 μM) significantly attenuated the cytotoxic 
effects of TNF plus CHX in EAhy926 cells in a 
concentration-dependent manner (P < 0.05) (Fig. 
4A). Comparable results were observed using a 
commercial cell viability kit measuring ATP content 
(P < 0.05) (Fig. 4B). 
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Figure 3. Curcumin attenuated endothelial cell activation. To determine the effects of curcumin on ICAM-1 
expressions, EAhy926 cells were pretreated with vehicle or curcumin (final DMSO concentration: 0.1%) for 1 hour and 
then exposed to TNF for 4 hours. Cells were analysed by flow cytometric analysis following staining with PE-CD54 
(ICAM-1). The results were expressed as (A) a percentage of induced ICAM-1 cells and (B) mean fluorescence 
intensity in arbitrary units. All results were expressed as mean ± S.E.M. from quadruplicate samples. # P < 0.05 
compared to blank. * P < 0.05 compared to TNF treated-group. (C) The adhesion of THP-1 cells to EAhy926 cells was 
assessed by crystal violet staining. Cell adhesion was expressed as fold change compared to control. All results were 
expressed as mean ± S.E.M. from three separate experiments. # P < 0.05 compared to control. * P < 0.05 compared to 
TNF treated-group. 
 
 
Curcumin attenuated TNF plus CHX-induced 
apoptotic events 
It is known that CHX can exacerbate TNF-induced 
apoptosis (24). To study the influence of curcumin 
on TNF plus CHX-mediated apoptotic events, 
EAhy926 cells were pretreated with curcumin for 1 
hour and then exposed to the combination of TNF 
(10 ng/mL) and CHX (100 ng/mL) for 24 hours. 
Our results demonstrated that the exposure of the 
cells to TNF plus CHX significantly elevated the 
proportion of EAhy926 cells with positive 
Annexin-V staining from 1.99 ± 0.05% to 15.82 ± 
0.40%. Pretreatment with curcumin (2.5 - 5 μM) 
significantly attenuated the apoptotic effects in a 
concentration-dependent manner (P < 0.05) (Fig 
4C).  
Apoptosis can also be described by the 
disruption of the mitochondrial membrane potential 
(∆ψm). Using a fluorescence probe (i.e. JC-1) to 
measure mitochondrial potentials, our results 
revealed that the proportion of cells with 
depolarised ∆ψm (as indicated by a reduction in 
JC-1 aggregate red to JC-1 monomer green 
fluorescence) were significantly increased in TNF 
plus CHX -treated EAhy926 cells from 21.11 ± 
1.39% to 37.97 ± 1.73%. Pretreatment with 
curcumin (2.5 - 5 μM) concentration-dependently 
reduced the proportion of cells with depolarised 
∆ψm (P < 0.05) (Fig 4D).  
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Figure 4. Curcumin attenuated endothelial cell death and apoptosis. Cell viability, as determined by (A) MTT dye 
reduction assay and (B) CellTiter®-Glo cell viability assay, following incubation with TNF plus CHX for 20 hours in 
EAhy926 endothelial cells which were pretreated with vehicle or curcumin (final DMSO concentration: 0.1%) for 1 
hour. Cell viability was expressed as a percentage compared to control. All results were expressed as mean ± S.E.M. 
from three separate experiments. # P < 0.05 compared to control in the respective cell lines. * P < 0.05 compared to 
TNF plus CHX treated-group. To determine the effects of curcumin on endothelial cell apoptosis, (C) flow cytometric 
analysis with FITC-Annexin-V and PI staining revealed that curcumin attenuated alterations in the exposure of 
membrane phospholipid phosphatidylserine, while (D) JC-1 staining showed that curcumin reduced the proportion of 
cells with depolarised ∆ψm (indicated by a reduction in JC-1 aggregate red to JC-1 monomer green fluorescence). All 
results were expressed as mean ± S.E.M. from quadruplicate samples. # P < 0.05 compared to control. * P < 0.05 
compared to TNF plus CHX treated-group. 
 
 
DISCUSSION 
 
The elevated levels of circulating endothelial 
microparticles are associated with endothelial 
dysfunction observed in hypertension, coronary 
artery diseases, ischaemic stroke, diabetes and other 
cardiovascular events (19,25-27). It has been 
suggested that these microparticles are implicated 
in the regulation of coagulation, oxidative stress, 
inflammation, angiogenesis and apoptosis (18,28). 
Therefore, therapeutic agents targeting 
microparticle release is an emerging strategy for 
cardiovascular diseases. Natural products such as 
turmeric represent a promising resource for the 
discovery of agents against microparticle 
generation. Here, we present the first evidence 
regarding the inhibitory effects of curcumin, a 
major curcuminoid in turmeric, on microparticle 
release from endothelial cells undergoing cell 
activation and cell death. In this study, 
microparticles are identified by an apoptotic marker, 
Annexin V, together with size cutoff at <1 µm, to 
minimize the interference of apoptotic bodies 
which are normally 1-4 µm in size (14). 
Under physiological conditions, cells release 
basal levels of microparticles (18). However, 
excessive microparticle generation can be triggered 
upon cell activation and apoptosis (18,29). In our 
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study, TNF elevated microparticle formation and 
this was shown by the shedding of vesicles with 
submicron size carrying phosphatidylserine. Our 
results showed that the pretreatment of curcumin 
reduced microparticle formation from endothelial 
cells enhanced by TNF. TNF is a well-known 
inducer of cell activation (30). Similar to previous 
reports, we demonstrated that TNF- induced cell 
activation reflected by the increased expressions of 
ICAM-1 and adhesion of monocytes to the 
endothelial monolayer (7). Our results further 
showed that these features were attenuated by the 
pretreatment of curcumin. These results support 
previous findings that curcumin suppressed 
ICAM-1 expressions and the adhesion of 
monocytes to TNF-activated human umbilical vein 
endothelial cells (21,31-33). Current literature has 
reported that these inhibitory effects are related to 
the role of curcumin in modulating 
inflammation-associated pathways (e.g. NF-κB and 
MAPK pathways) (31,33-35). These inflammatory 
pathways are known to be actively involved in the 
generation of microparticles (10,12). Further 
studies are warranted to evaluate the modulatory 
effects of curcumin on inflammatory pathways 
influencing microparticle generation. 
We also showed that the release of 
microparticles by TNF was further exacerbated 
through co-incubation with CHX, and this was 
attenuated by the pretreatment of curcumin. Cell 
death and apoptosis are important mechanisms 
involved in microparticle release. Similar to 
previous reports, we demonstrated that CHX 
exacerbated TNF-induced cytotoxicity (8). Our 
results further showed that curcumin exerted 
cytoprotective and anti-apoptotic effects in 
endothelial cells treated with TNF plus CHX. This 
is similar to previous reports showing that 
curcumin protects endothelial, neuronal and retinal 
epithelial cells from damage caused by oxidative 
stress and various toxins (36-38). We speculate that 
the reduction in microparticle levels under cell 
death conditions may be associated with the 
anti-apoptotic activities of curcumin. Further 
mechanistic studies are needed to address the action 
of curcumin on microparticle release which can be 
related to microparticle formation, or vesicle 
transport and release.   
In conclusion, curcumin reduced microparticle 
release from endothelial cells, which can be 
associated to its inhibitory effects against cell 
activation and cell death. These findings support 
curcumin as a promising nutraceutical candidate for 
vascular inflammatory diseases. 
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